Kazam Joshua A 4

What Happened

• Joshua A. Kazam, a director of Allogene Therapeutics (ALLO), was granted 95,400 Restricted Stock Units (RSUs) and reported exercise/conversion activity totaling 95,400 derivative units on 2026-06-18. All reported transactions show a $0.00 per-share price (total value $0 reported).
• The Form 4 shows two exercise/conversion entries of 47,700 shares each (one reported as "acquired" and one as "disposed"), and a separate award entry of 95,400 RSUs (acquired). No cash proceeds or purchase price are reported.

Key Details

• Transaction date: 2026-06-18; Filing date: 2026-06-23 (appears to be one business day late vs. the typical 2-business-day Form 4 deadline).
• Prices/values: all entries reported at $0.00 per share; reported total consideration $0.
• Shares owned after the transactions: not specified in the filing.
• Footnotes: F1/F2 state these are RSUs (contingent rights to one share or cash in lieu at the company’s discretion). F2 notes the RSUs vest in two equal semi-annual installments over one year from grant, subject to continued service.
• Transaction codes: M = exercise/conversion of derivative; A = grant/award. The disposed 47,700 derivative entry is reported as a derivative disposition.

Context

• The M-code activity indicates conversion/exercise of derivative securities. Reporting both an “acquired” and a simultaneous “disposed” derivative position for the same amount often reflects internal settlement/conversion or withholding procedures; the filing does not provide further detail.
• The RSU award is not an open-market purchase or sale and is primarily a compensation grant with vesting conditions, and the company can settle in shares or cash per the footnotes. Such grants and exercises are routine insider activity and do not by themselves indicate insider sentiment.